Conferencing Firm Soars 78% on Special Dividend

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

U.S. stock indexes retreated from record highs and ended mixed on Tuesday, as optimism over the Senate's passage of Trump's tax bill clashed with concerns about its cost, rate policy, and the tech sector's weakness.

Dollar General (NYSE: DG) is cutting prices on more than 1,000 essential items this summer to regain momentum with value-focused shoppers.

The company is expanding its discounting strategy to cover nearly half of its core product lines, a move it says is driven by growing economic strain among its customer base.

This shift is not about seasonal sales. It’s a strategic recalibration aimed at preserving volume as consumer budgets tighten.

The company is moving quickly to protect its share before higher input costs, including potential tariff effects, begin to bite.

For current shareholders, this pricing play underscores a broader tactical shift: Dollar General is choosing to lean into margin pressure now to avoid deeper volume losses later.

It's a defensive posture, but also one that may help stabilize comps in the quarters ahead.

Management appears to be prioritizing loyalty and traffic, even if it means less room for upside surprises in near-term earnings.

For those considering a new position, this is a real-time test of the company’s ability to operate effectively amid macroeconomic headwinds.

It’s a reminder that Dollar General’s strength isn’t just low prices, but agility and a willingness to adapt when demand softens.

Dollar General is not alone in adjusting course, but the scale and speed of this shift suggest it sees more risk ahead than peers are publicly acknowledging.

A successful portfolio is built on a strong foundation.

Our latest report, “7 Stocks to Buy and Hold Forever,” is designed to help you do just that—build a rock-solid base for long-term growth and stability no matter what the market does.

For a limited time, we’ve decided to release this report for free.

These 7 handpicked companies have shown consistent, reliable growth year after year, allowing investors peace of mind knowing their portfolio is built to last.

Get Your Report Today!

Start building your perfect portfolio to maximize your long-term returns today. Download this report while it’s still free!

Moderna (NASDAQ: MRNA) has released positive Phase 3 results for its mRNA-based seasonal flu vaccine, marking a potential breakthrough as the company pushes to expand beyond its COVID-era revenue base.

The vaccine, mRNA-1010, demonstrated statistically superior efficacy compared to a licensed standard-dose flu shot in adults aged 50 and older, achieving key endpoints across multiple flu strains.

This is Moderna’s first mRNA flu candidate to deliver strong efficacy in a full-scale trial, a milestone that moves it closer to filing for regulatory approval.

The trial enrolled more than 40,000 participants globally and showed efficacy across age groups and risk factors, key markers that support a viable commercial rollout.

For current shareholders, this is a necessary win. Moderna has faced pressure to prove that its pipeline can replace pandemic-era windfalls.

These results offer hard data that support confidence in the mRNA model beyond COVID.

If approved, the flu shot could become a recurring revenue anchor and lay the groundwork for a combined flu-COVID vaccine in the future.

Investors considering a position may now have stronger conviction in the company’s long-term roadmap.

With competitors like Sanofi and GSK entrenched in the flu market, Moderna still faces a fight for market share.

Moderna is expected to seek regulatory approval for mRNA-1010 following the release of this data, with potential commercialization as early as the next flu season.

Join over 4.5 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news.

From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost.

Experience news without the noise; let 1440 help you make up your own mind.

Sign up now and invite your friends and family to be part of the informed.

Ford (NYSE: F) is outpacing expectations, reporting strong performance across its core truck lineup and hybrid vehicles, signaling continued strength with utility-focused buyers even as pure EV adoption shows uneven momentum.

The highlight came from Ford’s F-Series trucks, which logged their best Q2 performance in years.

Hybrid vehicle sales also saw a solid boost, even as demand for fully electric models slipped.

Rather than pushing hard into unproven demand, Ford appears to be striking a middle path, leaning into powertrains that meet consumers where they are, not where the market hopes they’ll go.

For current investors, this performance suggests operational resilience and innovative portfolio management.

Ford is building sales volume through a balanced mix, rather than relying on high-risk EV adoption curves.

It also reinforces confidence in the company’s pricing power and retail channel strategy, which has come under pressure in recent quarters.

In a market where many automakers are offering incentives to clear inventory, Ford is gaining traction through demand, not discounts.

Ford is managing to grow while its competitors post more modest gains or depend on luxury margins.

While GM, Kia, and Hyundai are also seeing upticks, Ford’s diversified mix across segments shows broader market alignment.

Sales momentum alone doesn’t solve long-term transformation challenges.

But in the short term, Ford is outperforming and doing it without leaning too far ahead of its customer base.

👉 Click here to get our closing report to your cell for free!

ClearOne Inc [CLRO] $10.48 (+78.99%)

ClearOne, which offers business conferencing solutions, surged after announcing a one-time special dividend in the form of preferred shares tied to proceeds from a potential asset sale.

Blue Gold Limited [BGL] $71.95 (+73.67%)

Blue Gold shares continued to rally after listing on the Nasdaq a few days ago, driven by aggressive growth plans and acquisition opportunities in West Africa and Latin America.

Neurogene Inc [NGNE] $19.19 (+28.36%)

Neurogene rose after securing FDA agreement to begin a pivotal trial for its promising Rett syndrome treatment.

Cellectar Biosciences Inc [CLRB] $4.86 (-31.64%)

Cellectar shares dropped after pricing a heavily discounted public offering with attached warrants, raising $6 million in gross proceeds.

Aeva Technologies Inc [AEVA] $28.66 (-24.16%)

Aeva fell from yesterday’s 3-year high, as traders took profits after a 10x rally over three months that sent prices higher than the most bullish price targets from analysts.

Enhabit Inc [EHAB] $7.85 (-18.57%)

Enhabit slid after being removed from the Russell 2000 Growth Index, prompting index-tracking funds to exit positions.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.